Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$244M |
| 2 |
PFPT
Proofpoint, Inc.
PFPT
|
+$160M |
| 3 |
Fortive
FTV
|
+$157M |
| 4 |
KSU
Kansas City Southern
KSU
|
+$131M |
| 5 |
Truist Financial
TFC
|
+$118M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$169M |
| 2 |
Morgan Stanley
MS
|
+$151M |
| 3 |
BNY
Bank of New York Mellon
BNY
|
+$143M |
| 4 |
RP
RealPage, Inc.
RP
|
+$138M |
| 5 |
McDonald's
MCD
|
+$136M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.06% |
| 2 | Financials | 13.29% |
| 3 | Healthcare | 11.62% |
| 4 | Consumer Discretionary | 11.14% |
| 5 | Industrials | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1351
Avnet
AVT
$7.08B
| $860K | ﹤0.01% |
21,454
+8,758
| +69% | +$377K |
|
1352
PUT
Thermo Fisher Scientific
TMO
$232B
| $858K | ﹤0.01% |
+1,700
| New | +$802K |
|
1353
PUT
Zoetis
ZTS
$31.9B
| $857K | ﹤0.01% |
+4,600
| New | +$799K |
|
|
CSGS
1354
DELISTED
CSG Systems International
CSGS
| $856K | ﹤0.01% |
18,135
-5,994
| -25% | -$273K |
|
1355
Usana Health Sciences
USNA
$251M
| $856K | ﹤0.01% |
8,354
+3,954
| +90% | +$397K |
|
1356
PUT
Bristol-Myers Squibb
BMY
$137B
| $855K | ﹤0.01% |
+12,800
| New | +$835K |
|
1357
CALL
iShares MSCI Brazil ETF
EWZ
$8.07B
| $855K | ﹤0.01% |
2,250
-762,350
| -100% | -$28.8M |
|
1358
PUT
Merck
MRK
$372B
| $855K | ﹤0.01% |
+11,000
| New | +$818K |
|
1359
e.l.f. Beauty
ELF
$6.25B
| $853K | ﹤0.01% |
+31,442
| New | +$900K |
|
1360
PUT
Illumina
ILMN
$33.7B
| $852K | ﹤0.01% |
+1,850
| New | +$745K |
|
1361
PUT
Becton Dickinson
BDX
$52B
| $851K | ﹤0.01% |
+3,588
| New | +$860K |
|
1362
LXP Industrial Trust
LXP
$3.6B
| $848K | ﹤0.01% |
+14,186
| New | +$863K |
|
1363
FTC Solar
FTCI
$35.2M
| $844K | ﹤0.01% |
+6,341
| New | +$709K |
|
1364
PUT
Humana
HUM
$46.4B
| $841K | ﹤0.01% |
+1,900
| New | +$830K |
|
1365
PUT
Elevance Health
ELV
$87.3B
| $840K | ﹤0.01% |
+2,200
| New | +$841K |
|
1366
PUT
CVS Health
CVS
$120B
| $834K | ﹤0.01% |
+10,000
| New | +$819K |
|
1367
PUT
Danaher
DHR
$151B
| $832K | ﹤0.01% |
+3,497
| New | +$775K |
|
1368
PUT
Medtronic
MDT
$119B
| $832K | ﹤0.01% |
+6,700
| New | +$841K |
|
1369
PUT
Stryker
SYK
$126B
| $831K | ﹤0.01% |
+3,200
| New | +$818K |
|
1370
PUT
Edwards Lifesciences
EW
$52.2B
| $829K | ﹤0.01% |
+8,000
| New | +$754K |
|
|
IAS
1371
DELISTED
Integral Ad Science
IAS
| $823K | ﹤0.01% |
+40,000
| New | +$823K |
|
1372
PUT
AbbVie
ABBV
$467B
| $822K | ﹤0.01% |
+7,300
| New | +$822K |
|
1373
CALL
Abbott
ABT
$202B
| $812K | ﹤0.01% |
+7,000
| New | +$816K |
|
1374
PUT
Boston Scientific
BSX
$71B
| $812K | ﹤0.01% |
+19,000
| New | +$799K |
|
1375
Eagle Bancorp
EGBN
$857M
| $811K | ﹤0.01% |
14,457
-3,598
| -20% | -$199K |
|
Similar funds
Dmitry Balyasny's Q2 2021 Portfolio in Review
As of Q2 2021, Dmitry Balyasny held 2,666 positions worth $21.1B, up 4.1% from $20.3B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Dmitry Balyasny's Q2 2021 filing shows 960 new, 418 increased, 406 reduced and 754 closed positions. Its largest new stake was Nuance Communications, Inc.: 4,636,095 shares worth $252M. The largest sale was Bank of America, an estimated $169M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- Dmitry Balyasny's largest Q2 2021 buy was Nuance Communications, Inc.: 4,636,095 shares worth $252M.
- Dmitry Balyasny added most to QTS REALTY TRUST, INC. in Q2 2021, an estimated $91.6M increase.
- Dmitry Balyasny's biggest Q2 2021 reduction was Morgan Stanley, cutting an estimated $151M.
- Dmitry Balyasny fully exited Bank of America in Q2 2021, selling an estimated $169M.
- Dmitry Balyasny's ten largest holdings make up 11% of its $21.1B portfolio in Q2 2021.
- Dmitry Balyasny opened 960 new positions and closed 754 in Q2 2021.
- Dmitry Balyasny's portfolio value rose 4.1% quarter-over-quarter to $21.1B.
Based on Balyasny Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.